Literature DB >> 455317

Phase II trial of vindesine in patients with malignant lymphoma.

R B Sklaroff, D Straus, C Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 455317

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Vindesine effect in myeloid leukemia.

Authors:  M Baccarani; A Zaccaria; G Corbelli; S Tura
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).

Authors:  D J Straus; J Myers; B Koziner; B J Lee; B D Clarkson
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study.

Authors:  N J DiBella; R Berris; D Garfield; K Fink; J Speer; A Sakamoto
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Phase-I-II study of high-dose melphalan and autologous marrow transplantation in adult patients with poor-risk non-Hodgkin's lymphomas.

Authors:  B Mascret; D Maraninchi; J A Gastaut; D Baume; G Sebahoun; C Lejeune; G Novakovitch; D Sainty; N Horchowski; N Tubiana
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.